Sanmai Technologies PBC

Sanmai operates at the intersection of neuroscience, therapeutics, and medical devices, with a focus on non-invasive neuromodulation for mental health and neurological conditions. Its stated approach uses transcranial focused ultrasound rather than an implanted brain-computer interface, and its acoustic planning software is intended to personalize targeting and compensate for skull-related distortion. Neuralink is the most visible named point of comparison in coverage of Sanmai, but the companies’ described modalities differ: Sanmai focuses on ultrasound neuromodulation, while Neuralink is associated with implanted brain-computer interfaces. That distinction does not establish that the companies address identical clinical use cases or compete directly. The company is categorized in medical devices, neuroscience, and therapeutics and had a reported Series A stage as of Jun 23, 2025. The potential differentiator is the combination of non-invasive ultrasound hardware with personalized acoustic planning, rather than a broad software platform or general-purpose AI product. Clinical evidence, regulatory status, commercial availability, and comparative performance are not sufficiently detailed to assess its standing against established neuromodulation treatments or other focused-ultrasound developers.

Sanmai was founded in 2020 and is developing a focused-ultrasound neuromodulation device and supporting acoustic planning software. Its principal financing inflection point in the available timeline is the $12 million Series A announced on Jun 23, 2025, led by Reid Hoffman and joined by Future Ventures and PsyMed Ventures. The company lists a team size in the 1–10 employee range, and its CEO and co-founder, Jay Sanguinetti, has held that role since August 2021. A careers page and active team-building signal point to ongoing hiring, although specific open roles or hiring targets are not given. As a result, the visible trajectory is that of an early-stage neurotechnology company progressing from founding toward clinical evaluation, with a material 2025 financing event. Evidence of scale-up beyond the reported small team, commercialization, or later-stage clinical validation is limited.